This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Horizon (HZNP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Horizon (HZNP) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 2.
Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Bayer (BAYRY) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Nov 3.
Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.
Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote
by Zacks Equity Research
Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.
LGND or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ALKS: Which Stock Is the Better Value Option?
LGND or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. ALKS: Which Stock Is the Better Value Option?
Why Is Alkermes (ALKS) Down 12% Since Last Earnings Report?
by Zacks Equity Research
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
by Zacks Equity Research
Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
ANIK or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 700.00% and 3.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines (VBIV) to Report Q2 Earnings: What's in Store
by Zacks Equity Research
VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.
ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.
Why Alkermes (ALKS) Might Surprise This Earnings Season
by Zacks Equity Research
Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axcella (AXLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.
Soleno (SLNO) to report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) will provide financial and corporate updates when it releases second-quarter 2020 results on Jul 30.
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.